Want create site? Find Free WordPress Themes and plugins.
dnalong cut new logo

About BioNeb Limited

Bioneb Limited, (hereinafter "Bioneb” or the “Company") is a corporation incorporated under the Laws of England and Wales located with its registered office at 82 St John Street, London, EC1M 4JA, United Kingdom.

BioNeb’s (“The Company”) goal is to be a leader in the delivery of Bio~logics and Bio~Similars medical  formulations,  insulin formulations, registered antibiotics and drug formulations ,viral formulations, nicotine formulations, medical marijuana formulations, vitamin formulations, weight loss formulations and recreational formulations. The Company specialises in the research and development of a pulmonary micro droplet medical delivery systems using  Ultrasonic  Atomizing Vibrating Micron Micro Mesh (MMM) disc Technology for the pulmonary uptake of Pharmaceutical Grade B medical drug formulations. 

Our Ultrasonic  Atomizing Vibrating  Micron Micro Mesh (MMM) disc drug delivery patent approved and patent pending  devices are all FDA 510K approved and are able to efficiently deliver FDA approved  bio~logic and bio~similar medical formulations ,insulin formulations , registered antibiotics and drug formulations ,viral formulations.

 

Nicotine formulations, medical marijuana formulations, vitamin formulations, weight loss formulations and recreational formulations currently do not need FDA approval but the Company intends seeking FDA approvals for these formulations. 

 

The Company has also Trademarked Micron Micro Mesh (MMM) vibrating micro mesh delivery devices and  submitted numerous patent pending  FDA approved bio~logic and bio~similar,insulin formulations, registered antibiotics and drug formulations, viral formulations, nicotine formulations, medical marijuana formulations,  vitamin formulations, weight loss formulations and recreational  hypertonic saline medical  formulations.

 

The goal is to provide the ability to deliver  bio~logic , bio~similar insulin formulations , registered antibiotics and drug formulations ,viral formulations, nicotine formulations, medical marijuana formulations ,  vitamin formulations , weight loss formulations and recreational formulations and common drug formulations  more efficiently than current methods.

 

Agreements are in place with the only FDA approved production facilities which  manufacture  and assemble all the FDA 510K approved Ultrasonic  Atomizing Vibrating  Micron Micro Mesh (MMM) disc drug delivery devices .

bioneb2

BioNeb’s (“The Company”) goal is to be a leader in the delivery of Bio~logics and Bio~Similars medical  formulations,  insulin formulations, registered antibiotics and drug formulations ,viral formulations, nicotine formulations, medical marijuana formulations, vitamin formulations, weight loss formulations and recreational formulations. The Company specializes in the research and development of a pulmonary micro droplet medical delivery systems using  Ultrasonic  Atomizing Vibrating Micron Micro Mesh (MMM) disc Technology for the pulmonary uptake of Pharmaceutical Grade B medical drug formulations. 

Our Ultrasonic  Atomizing Vibrating  Micron Micro Mesh (MMM) disc drug delivery patent approved and patent pending  devices are all FDA 510K approved and are able to efficiently deliver FDA approved  bio~logic and bio~similar medical formulations ,insulin formulations , registered antibiotics and drug formulations ,viral formulations.

 

Nicotine formulations, medical marijuana formulations, vitamin formulations, weight loss formulations and recreational formulations currently do not need FDA approval but the Company intends seeking FDA approvals for these formulations. 

 

The Company has also Trademarked Micron Micro Mesh (MMM) vibrating micro mesh delivery devices and  submitted numerous patent pending  FDA approved bio~logic and bio~similar,insulin formulations, registered antibiotics and drug formulations, viral formulations, nicotine formulations, medical marijuana formulations,  vitamin formulations, weight loss formulations and recreational  hypertonic saline medical  formulations.

 

The goal is to provide the ability to deliver  bio~logic , bio~similar insulin formulations , registered antibiotics and drug formulations ,viral formulations, nicotine formulations, medical marijuana formulations ,  vitamin formulations , weight loss formulations and recreational formulations and common drug formulations  more efficiently than current methods.

 

Agreements are in place with the only FDA approved production facilities which  manufacture  and assemble all the FDA 510K approved Ultrasonic  Atomizing Vibrating  Micron Micro Mesh (MMM) disc drug delivery devices .

bioneb2

Bioneb Limited Trademarks,Patents and Approvals

  • The trade mark Micron Micro Mesh (MMM) had been registered in the USA, UK , EU and the Madrid Trademark registry. 

  • The original IP for the “Droplet Generation Apparatus" has been approved in the USA, China. 510K approval granted.

  • Patents are  pending  for the original “Droplet Generation Apparatus “ for the UK, EU and World Intellectual Property Organization (WIPO) .

  • The following patents have been registered and are pending in the US, UK, EU and WIPO 

Bioneb Limited Trademarks,Patents and Approvals

The trade mark Micron Micro Mesh (MMM) had been registered in the USA, UK , EU and the Madrid Trademark registry. 

 

The original IP for the “Droplet Generation Apparatus" has been approved in the USA, China. 510K approval granted.

 

Patents are  pending  for the original “Droplet Generation Apparatus “ for the UK, EU and World Intellectual Property Organization (WIPO) .

 

The following patents have been registered and are pending in the US, UK, EU and WIPO 

bioneb patents

 

The IP has been approved in the USA, China and pending for the EU and rest of the world in the name of e nicotine systems Asia. The patents for the juice formulations are in the process of being patented and will belong to eNicotine Systems Asia Ltd. (ENSA) for USA and Asia Pacific and for the EU and rest of the world. ENSA have an exclusive license agreement with Health & Life to use their 510 K approved HL-100 Patent US 7,607,589 B2 “Droplet Generation Apparatus” for the e8000 and e8000-2 series products and any future products currently under development.

 

Analytical data (i.e. full aerosol size distributions across multiple batches, and delivered dose data across multiple puffs and multiple devices): ENSA, H&L have in house data for medication aerosol performance verification and validation test report for HL-100. We use the same HL-100 mesh and technology in the newly modified exterior shell of e8000 and e8000-2. Eighteen (18) test reports were submitted to obtain our 510K for FDA and CE approval.

 

The factory of manufacture is FDA approved, one of only two in Asia Pacific : GMP, FMEA, strict quality control, CE and 510K approval were obtained for HL-100 and the e8000 and e8000-2 use the same technology with different outer shell designs The same production lines and processes will be followed in the factory for the production of the e8000 and e8000-2 and other products under development. Stock exchange listed company, www.healthandlife.com.tw

 

RoHs and REACH approval obtained for HL-100 device and materials. The same materials are being used for e8000 and e8000-2. RoHs and REACH approval will be obtained similarly prior to mass production.

 

The mesh plate is made of a unique combination of palladium and alloy nickel in a patented process. This is unique and superior to our competitor’s plastic and stainless steel mesh which breaks down and produces toxic substances over time. Our mesh design and composition are ultrafine, strong and stable.

 

40 hectare factory facility in Suzhou, China. FDA certified manufacturing facility with ISO 13485, CE 0197, CE 0537 FDA 510K approvals. Three lines currently operation for manufacture with ample space for expansion. Current capacity 100,000 units per month per line. Ready for production immediately

 

The IP has been approved in the USA, China and pending for the EU and rest of the world in the name of e nicotine systems Asia. The patents for the juice formulations are in the process of being patented and will belong to eNicotine Systems Asia Ltd. (ENSA) for USA and Asia Pacific and for the EU and rest of the world. ENSA have an exclusive license agreement with Health & Life to use their 510 K approved HL-100 Patent US 7,607,589 B2 “Droplet Generation Apparatus” for the e8000 and e8000-2 series products and any future products currently under development.

 

Analytical data (i.e. full aerosol size distributions across multiple batches, and delivered dose data across multiple puffs and multiple devices): ENSA, H&L have in house data for medication aerosol performance verification and validation test report for HL-100. We use the same HL-100 mesh and technology in the newly modified exterior shell of e8000 and e8000-2. Eighteen (18) test reports were submitted to obtain our 510K for FDA and CE approval.

 

The factory of manufacture is FDA approved, one of only two in Asia Pacific : GMP, FMEA, strict quality control, CE and 510K approval were obtained for HL-100 and the e8000 and e8000-2 use the same technology with different outer shell designs The same production lines and processes will be followed in the factory for the production of the e8000 and e8000-2 and other products under development. Stock exchange listed company, www.healthandlife.com.tw

 

RoHs and REACH approval obtained for HL-100 device and materials. The same materials are being used for e8000 and e8000-2. RoHs and REACH approval will be obtained similarly prior to mass production.

 

The mesh plate is made of a unique combination of palladium and alloy nickel in a patented process. This is unique and superior to our competitor’s plastic and stainless steel mesh which breaks down and produces toxic substances over time. Our mesh design and composition are ultrafine, strong and stable.

 

40 hectare factory facility in Suzhou, China. FDA certified manufacturing facility with ISO 13485, CE 0197, CE 0537 FDA 510K approvals. Three lines currently operation for manufacture with ample space for expansion. Current capacity 100,000 units per month per line. Ready for production immediately

Did you find apk for android? You can find new Free Android Games and apps.